Mga Batayang Estadistika
| CIK | 1827401 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bright Minds Biosciences Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
For Immediate Release Bright Minds Biosciences Announces BMB‑201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model New York, New York — September 4, 2025 — Bright Minds Biosciences Inc. |
|
| September 5, 2025 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of princip |
|
| August 26, 2025 |
Calculation of Filing Fee Tables F-3 BRIGHT MINDS BIOSCIENCES INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forwa |
|
| August 26, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 26, 2025 |
BRIGHT MINDS BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENT BRIGHT MINDS BIOSCIENCES INC. EQUITY DISTRIBUTION AGREEMENT August 25, 2025 PIPER SANDLER & CO. 350 North 5th Street, Suite 1000 Minneapolis, MN 55401 CANTOR FITZGERALD & CO. 110 East 59th Street New York, New York 10022 Ladies and Gentlemen: As further set forth in this agreement (this "Agreement"), Bright Minds Biosciences Inc., a company organized under the laws of the Province of British Colum |
|
| August 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 15, 2025 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) June 30, September 30, As at Notes 2025 (unaudited) 2024 (audited) $ $ ASSETS Current Assets Cash and cash equi |
|
| August 15, 2025 |
BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June |
|
| August 15, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| August 15, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| August 11, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| August 11, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| August 11, 2025 |
BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2025 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma |
|
| August 11, 2025 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2025 and 2024 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2025 (unaudited) 2024 (audited) $ $ ASSETS Current Assets Cash and cash equ |
|
| May 28, 2025 |
Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference FOR IMMEDIATE RELEASE Bright Minds Biosciences to Present at the 2025 Jefferies Global Healthcare Conference New York and Vancouver, BC – May 28, 2025 – Bright Minds Biosciences, Inc. |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 21, 2025 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal exe |
|
| May 21, 2025 |
FOR IMMEDIATE RELEASE Bright Minds Biosciences Announces Featured Speakers for its Absence Epilepsy Virtual R&D Day on May 20, 2025 - Key Opinion Leaders (KOLs) on Absence seizures include Dennis Dlugos, MD, Wendyl D’Souza, MBChB, MPH, FRACP, PhD, and Alexander Rotenberg, MD, PhD - Vancouver, British Columbia, May 20, 2025 - Bright Minds Biosciences Inc. |
|
| May 14, 2025 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal exe |
|
| May 14, 2025 |
FOR IMMEDIATE RELEASE Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101 -BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - -The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - -Findings highlight BMB-101’s potential to address critical gaps in SUDEP prevention - New York and Vancouver, British Columbia, May 13, 2025 - Bright Minds Biosciences Inc. |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| April 29, 2025 |
FOR IMMEDIATE RELEASE Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study Vancouver, British Columbia, April 28, 2025 - Bright Minds Biosciences Inc. |
|
| March 5, 2025 |
FOR IMMEDIATE RELEASE Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research - Dennis Dlugos, MD, MSCE; Jacqueline French, MD; Terrence O'Brien, MD; Jo Sourbron, MD, PhD, MPharm; and Joseph Sullivan, MD, bring decades of experience in epilepsy drug development and research to support Company’s clinical focus on epilepsy – Vancouver, British Columbia, March 4, 2025 - Bright Minds Biosciences Inc. |
|
| March 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| February 24, 2025 |
Bright Minds Biosciences to Participate at Three Healthcare Conferences in March Bright Minds Biosciences to Participate at Three Healthcare Conferences in March New York and Vancouver, BC – February 24, 2025 – Bright Minds Biosciences, Inc. |
|
| February 24, 2025 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa |
|
| February 14, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| February 14, 2025 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter ended D |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| February 14, 2025 |
BRIGHT MINDS BIOSCIENCES INC. 1,612,902 Common Shares Filed Pursuant to Rule 424(b)(3) Registration No. 333-284694 Prospectus BRIGHT MINDS BIOSCIENCES INC. 1,612,902 Common Shares This prospectus relates to the resale of up to 1,612,902 common shares (the "Common Shares") of Bright Minds Biosciences Inc. (the "Company") that may be offered and sold, from time to time, by the selling securityholders identified in this prospectus. These shares consist |
|
| February 14, 2025 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| February 14, 2025 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2024 and 2023 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2024 (unaudited) 2024 (audited) $ $ ASSETS Current Assets |
|
| February 12, 2025 |
VIA EDGAR Correspondence February 12, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BRIGHT MINDS BIOSCIENCES INC. (Exact name of registrant as specified in its charter) British Columbia (State or other jurisdiction of incorporation or organization) N/A (I.R.S. Employer Identification Number) 19 Vestry Street, New York, NY 10013 (604) 689-9111 (A |
|
| February 5, 2025 |
COMMON SHARE SUBSCRIPTION AGREEMENT CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL COMMON SHARE SUBSCRIPTION AGREEMENT TO: Bright Minds Biosciences Inc. |
|
| February 5, 2025 |
Exhibit 107 Calculation of Filing Fee Tables FORM F-3 (Form Type) BRIGHT MINDS BIOSCIENCES INC. |
|
| January 8, 2025 |
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Dr. Collins brings extensive drug development and clinical expertise in epilepsy - New York and Vancouver, BC – January 7, 2025 – Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 ag |
|
| January 8, 2025 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| December 31, 2024 |
DESCRIPTION OF REGISTRANT'S SECURITIES EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act ( |
|
| December 31, 2024 |
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2024 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our |
|
| December 31, 2024 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| December 31, 2024 |
BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") INSIDER TRADING, REPORTING AND BLACKOUT POLICY BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") INSIDER TRADING, REPORTING AND BLACKOUT POLICY This Insider Trading, Reporting and Blackout Policy (the "Policy") should be read in conjunction with each of the Corporation's current Securities Trading and Reporting Guidelines and Corporate Disclosure Policy. Purpose The purpose of this Policy is to further explain certain legal concepts with respe |
|
| December 31, 2024 |
BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") CYBERSECURITY POLICY BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") CYBERSECURITY POLICY Purpose The Board of Directors of the Corporation has adopted this Cybersecurity Policy (or the "Policy" as the context provides for) with a purpose of serving as a standard for setting, reviewing and implementing the Corporation's cybersecurity goals, objectives and targets. The "Corporation" includes Bright Minds Biosciences |
|
| December 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| December 31, 2024 |
BRIGHT MINDS BIOSCIENCES INC. INDEPENDENT CONTRACTOR AGREEMENT 1 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
|
| December 31, 2024 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 21, 2024 |
For Immediate Release Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, November 21, 2024 - Bright Minds Biosciences Inc. |
|
| November 12, 2024 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 12, 2024 is by and among RA Capital Management, L. |
|
| November 12, 2024 |
DRUG / Bright Minds Biosciences Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment SC 13G 1 tm2427451d4sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) November 4, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) November 4, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| November 5, 2024 |
DRUG / Bright Minds Biosciences Inc. / McDonald Ian - FORM SC 13D/A Activist Investment SC 13D/A 1 formsc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 3)* Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Addres |
|
| November 5, 2024 |
BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT BRIGHT MINDS BIOSCIENCES CLOSES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, November 4, 2024 - Bright Minds Biosciences Inc. |
|
| November 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 5, 2024 |
DRUG / Bright Minds Biosciences Inc. / McDonald Ian - FORM SC 13D/A Activist Investment SC 13D/A 1 formsc13da.htm FORM SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 4)* Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Addres |
|
| October 25, 2024 |
DRUG / Bright Minds Biosciences Inc. / COMMODORE CAPITAL LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 18, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| October 23, 2024 |
DRUG / Bright Minds Biosciences Inc. / Logos Global Management LP Passive Investment SC 13G 1 drug13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) October 16, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| October 23, 2024 |
SC 13G 1 p24-2994sc13g.htm BRIGHT MINDS BIOSCIENCES INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 16, 2024 (Date of Event Which Requires Filing of this Statement) Che |
|
| October 23, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-2994exhibit991.htm JOINT FILING AGREEMENT EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing |
|
| October 22, 2024 |
DRUG / Bright Minds Biosciences Inc. / PFM Health Sciences, LP - SC 13G/A Passive Investment SC 13G/A 1 tm2426599d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1)* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares, Without Par Value (Title of Class of Securities) 10919W405 (CUSIP Number) Octob |
|
| October 22, 2024 |
EX-99.1 2 tm2426599d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Bright Minds Biosciences Inc., a Canadian corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange |
|
| October 22, 2024 |
DRUG / Bright Minds Biosciences Inc. / Cormorant Asset Management, LP Passive Investment SC 13G 1 sc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 10919W405 (CUSIP Number) October 15, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| October 22, 2024 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 22, 2024, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with |
|
| October 21, 2024 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| October 21, 2024 |
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data NEW YORK AND VANCOUVER, October 21, 2024 – Bright Minds Biosciences Inc. |
|
| October 18, 2024 |
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES US$35 MILLION NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, October 18, 2024 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) i |
|
| October 18, 2024 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| October 16, 2024 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| October 16, 2024 |
EXHIBIT 99.1 Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models BMB-201 demonstrated dose-dependent efficacy in pain models BMB-201 demonstrated similar efficacy to morphine in several pain models NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a pioneering co |
|
| October 16, 2024 |
UNAWARE OF ANY MATERIAL CHANGES UNAWARE OF ANY MATERIAL CHANGES Vancouver, British Columbia, October 15, 2024 – At the request of CIRO, Bright Minds Biosciences Inc. |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive |
|
| October 16, 2024 |
DRUG / Bright Minds Biosciences Inc. / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Bright Minds Biosciences Inc (Name of Issuer) Common Shares, without par value (Title of Class of Securities) 10919W405 (CUSIP Number) October 14, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| October 16, 2024 |
EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: October 16, 2024 PERCEPTIVE ADVISORS LLC B |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive |
|
| October 3, 2024 |
EXHIBIT 99.1 Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events Bright Minds Biosciences will present scientific posters about various programs in development, including BMB-101, BMB-201 and BMB-202 Bright Minds Biosciences will participate in BIO Europe partnering event and Chicago Biocapital Summit to present its innovation in neuroscience N |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive o |
|
| September 12, 2024 |
Bright Minds Biosciences Initiates Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy ·Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs ·BMB-101 is a novel highly selective 5-HT2C agonist. |
|
| August 15, 2024 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June |
|
| August 15, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| August 15, 2024 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) 1 | P a g e Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) June 30, September 30, As at Notes 2024 (unaudited) 2023 (audited) $ $ ASSETS Current A |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 15, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| May 17, 2024 |
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES BRIGHT MINDS BIOSCIENCES ANNOUNCES RESULTS OF AGM Vancouver, British Columbia, March 27, 2024 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company"), a leading biotechnology company |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| May 17, 2024 |
510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com Date: January 11, 2024 To: All Canadian Securities Regulatory Authorities Subject: BRIGHT MINDS BIOSCIENCES INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type: Annual General Meeting Record Date for Notice of Meeting: February 05, 2024 Rec |
|
| May 17, 2024 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2024 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma |
|
| May 17, 2024 | ||
| May 17, 2024 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the six months ended March 31, 2024 and 2023 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2024 (unaudited) 2023 (audited) $ $ ASSETS Current Assets Cash and cash equ |
|
| May 17, 2024 |
BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the "Meeting") of shareholders (the "Shareholders") of Bright Minds Biosciences Inc. (the "Company") will be held at the offices of McMillan LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia V6E 4N7 on Friday, March 22, 2024, at 10:00 a.m. (Pac |
|
| May 17, 2024 | ||
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 17, 2024 |
BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 5, 2024, except as otherwise noted) This Management Information Circular ("Circular") is furnished in connection with the solicitation of proxies by the management of Bright Minds Biosciences Inc. (the "Company") for use at the annual general meeting (the "Meeting") of the Company's sh |
|
| May 17, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| May 17, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| February 26, 2024 |
DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment SC 13D/A 1 sc13da2-im.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC Dubai, United Arab Emirates (Name, Address and Telephone |
|
| February 26, 2024 |
DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment SC 13D/A 1 sc13da1-im.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald Park Towers B804, DIFC, Dubai, UAE (Name, Address and Telephone Number of Person |
|
| February 13, 2024 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2023 (unaudited) 2023 (audited) $ $ ASSETS Current Assets |
|
| February 13, 2024 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter ended D |
|
| February 13, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| February 13, 2024 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| January 18, 2024 |
DRUG / Bright Minds Biosciences Inc. / McDonald Ian Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 BRIGHT MINDS BIOSCIENCES INC. (Name of Issuer) COMMON STOCK, WITHOUT PAR VALUE (Title of Class of Securities) 10919W405 (CUSIP Number) Ian McDonald 560 King Street West Toronto, Ontario, Canada, M5V 0L5 (Name, Address and Telephone Number of Person Authorized to Receive No |
|
| December 29, 2023 |
EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| December 29, 2023 | ||
| December 29, 2023 |
BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") SECURITIES TRADING AND REPORTING GUIDELINES BRIGHT MINDS BIOSCIENCES INC. (the "Corporation") SECURITIES TRADING AND REPORTING GUIDELINES These Securities Trading and Reporting Guidelines (the "Guidelines") are to be read in conjunction with the Corporation's Corporate Disclosure Policy. Objectives The Corporation's commitment to ethical and lawful business conduct is a fundamental shared value of the Corporation's Board of Directors (the " |
|
| December 29, 2023 |
BRIGHT MINDS BIOSCIENCES INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION (the "Recovery Policy") As adopted by the Board of Directors on December 1, 2023 1. GENERAL PROVISIONS Purpose (a) This Recovery Policy has been adopted by resolution of the Board (as hereinafter defined) in accordance with certain listing standards of the Nasdaq Stock Market LLC mandated by S |
|
| December 29, 2023 |
EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| December 29, 2023 |
DESCRIPTION OF REGISTRANT'S SECURITIES EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act ( |
|
| December 29, 2023 |
EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2023 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our |
|
| December 26, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa |
|
| December 26, 2023 |
Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Bright Minds Announces Closing of Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia, December 22, 2023 – Bright Minds Biosciences Inc. |
|
| December 8, 2023 |
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Announces Non-Brokered Private Placement Fully Subscribed by Management Vancouver, British Columbia, December 6, 2023 - Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Compan |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| August 15, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| August 15, 2023 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter ended June |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 15, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| August 15, 2023 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) June 30, September 30, As at Notes 2023 (unaudited) 2022 (audited) $ $ ASSETS Current Assets |
|
| August 8, 2023 |
For Immediate Release Bright Minds Biosciences Announces Positive qEEG (Quantitative Electroencephalogram) Data from its First-in-Human Phase 1 Study of Lead Compound, BMB-101 - BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders - qEEG study was conduct |
|
| August 8, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| July 20, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal ex |
|
| July 20, 2023 |
For Immediate Release Bright Minds Biosciences Announces Positive Topline Data for its First-in-Human Phase 1 Study of Lead Compound, BMB-101 - BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders - BMB-101 demonstrated an excellent safety and tolerability profile in single ascending dose, multiple ascending dose and food effects study - BMB-101 demonstrated central target engagement and predictable plasma pharmacokinetics Vancouver, British Columbia, July 20, 2023 – Bright Minds Biosciences Inc. |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office |
|
| July 12, 2023 |
Bright Minds Announces Effective Date of Share Consolidation Bright Minds Announces Effective Date of Share Consolidation Vancouver, British Columbia, July 11, 2023 – Bright Minds Biosciences Inc. |
|
| June 22, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal ex |
|
| June 22, 2023 |
Bright Minds Announces Proposed Share Consolidation Bright Minds Announces Proposed Share Consolidation Vancouver, British Columbia, June 22, 2023 – Bright Minds Biosciences Inc. |
|
| May 15, 2023 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2023 and 2022 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) March 31, September 30, As at Notes 2023 (unaudited) 2022 (audited) $ $ ASSETS Current Asset |
|
| May 15, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| May 15, 2023 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2023 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter ended Ma |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 15, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| April 19, 2023 |
For Immediate Release Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202 - BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B – - BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds – Vancouver, British Columbia, April 19, 2023 – Bright Minds Biosciences Inc. |
|
| April 19, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal e |
|
| April 10, 2023 |
EXHIBIT 99.1 Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research — Presentation entitled "BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility" — — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia — VANCOUVER, British Columbia, April 10, 2023 (GLOBE NEWSWIRE) - Bright Mi |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-40997 Bright Minds Biosciences Inc. (Translation of registrant's name into English) 19 Vestry Street New York, NY 10013 (Address of principal executive of |
|
| March 2, 2023 | ||
| March 2, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal e |
|
| March 2, 2023 |
January 20, 2023510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: BRIGHT MINDS BIOSCIENCES INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type :Annual General Meeting Record Date for Notice of Meeting :February 15, |
|
| March 2, 2023 |
BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 24, 2023 AND INFORMATION CIRCULAR This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred to in this notice and information circular, you should immediately contact your advisor. BRIGHT MINDS BIOSCIEN |
|
| March 2, 2023 |
Proxy Card relating to Annual General Meeting of Shareholders to be held on |
|
| February 27, 2023 |
Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023 - First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway in Australia - - Company has transitioned from a discovery to a development organization – - Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 - Vancouver, British Columbia, February 27, 2023 – Bright Minds Biosciences Inc. |
|
| February 27, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa |
|
| February 17, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principa |
|
| February 17, 2023 |
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES Bright Minds Biosciences Announces Non-Executive Director Appointment - David Weiner, MD, brings extensive experience in the discovery and clinical development of novel therapeutics for neurological, psychiatric and rare |
|
| February 8, 2023 |
EX-99.1 2 ex991-20230208drug.htm NEWS RELEASE BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ DEFICIENCY LETTER REGARDING INDEPENDENT DIRECTOR AND AUDIT COMMITTEE REQUIREMENTS Vancouver, British Columbia, February 8, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”) announces that it has received a letter (the “Deficiency Letter”) from the Nasdaq |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| February 7, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Bright Minds Biosciences Inc. (the "issuer") for the interim period ended December 31, 202 |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| February 7, 2023 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2022 and 2021 (Expressed in Canadian Dollars) 1 | Page Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars) December 31, September 30, As at Notes 2022 (unaudited) 20 |
|
| February 7, 2023 |
Studies Completed & Other Milestones Accomplished: EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2022 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financia |
|
| February 7, 2023 |
Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Bright Minds Biosciences Inc. (the "issuer") for the interim period ended December 31, 20 |
|
| January 30, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| January 30, 2023 |
Bright Minds Biosciences Announces Resignation of Board Member EX-99.1 2 ex991-20230109drug.htm NEWS RELEASE For Immediate Release Bright Minds Biosciences Announces Resignation of Board Member Vancouver, BC – January 9, 2023 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today |
|
| January 27, 2023 |
BRIGHT MINDS BIOSCIENCES ANNOUNCES RECEIPT OF NASDAQ NOTIFICATION LETTER REGARDING MINIMUM BID PRICE DEFICIENCY Vancouver, British Columbia, January 27, 2023 – Bright Minds Biosciences Inc. |
|
| January 27, 2023 |
UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2023 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal |
|
| December 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| December 29, 2022 |
Section 302(a) Certification of CFO* EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| December 29, 2022 |
Section 302(a) Certification of CEO* EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| December 29, 2022 |
Independent Contractor Agreement with Dr. Mark A. Smith dated December 1, 2022*+ EX-4.24 3 exhibit4-24.htm EXHIBIT 4.24 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. BRIGHT MINDS BIOSCIENCES INC. INDEPENDENT CONTRACTOR AGREEMENT THIS INDEPENDENT CONTRACTOR AGREEMENT (this "Agreement") is dated effective December 1, 2022 BETWEEN: BRIGHT MINDS BIOSCIENCES INC. |
|
| December 29, 2022 |
Section 906 Certifications of CEO and CFO* EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2021 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our |
|
| December 29, 2022 |
Agency Agreement between the Company and Eight Capital dated August 25, 2022*+ CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. |
|
| December 29, 2022 |
EX-4.26 5 exhibit4-26.htm EXHIBIT 4.26 CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. BRIGHT MINDS BIOSCIENCES INC. as the Corporation and COMPUTERSHARE TRUST COMPANY OF CANADA as the Warrant Agent WARRANT INDENTURE Providing for the Issue of Warrants Dated as of August 30, 2022 |
|
| December 29, 2022 |
Description of Registrant's Securities* EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act ( |
|
| December 6, 2022 |
BRIGHT MINDS BIOSCIENCES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 29, 2022 |
BRIGHT MINDS BIOSCIENCES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BRIGHT MINDS BIOSCIENCES ANNOUNCES NON-BROKERED PRIVATE PLACEMENT Vancouver, British Columbia, November 28, 2022 - Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) ("Bright Min |
|
| November 23, 2022 |
EX-99.1 2 ex991-20221123drug.htm NEWS RELEASE For Immediate Release Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer - Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise - Vancouver, BC – November 23, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” |
|
| November 23, 2022 |
6-K 1 f6k-20221123drug.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Addres |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive o |
|
| September 8, 2022 |
For Immediate Release Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome - In predictive animal models, BMB-101 demonstrated significant reduction in both the number and intensity of epileptic seizures - Vancouver, BC ? August 31, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that it has dosed the first patient in a Phase I trial (NCT 05397041) for its lead product, BMB-101, for the treatment of Dravet Syndrome and other medical indications. |
|
| September 8, 2022 |
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors NOT FOR DISTRIBUTION TO U. |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 30, 2022 |
PRESS RELEASE August 30, 2022 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. |
|
| August 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 29, 2022 |
BRIGHT MINDS BIOSCIENCES INC. OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS BRIGHT MINDS BIOSCIENCES INC. OVERNIGHT MARKETED PUBLIC OFFERING OF UNITS FINAL TERM SHEET AUG 23, 2022 A final short form base shelf prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in each of the Provinces of Canada, other than Quebec. Copies of the final short form base shelf prospectus an |
|
| August 29, 2022 |
AGENCY AGREEMENT August 25, 2022 Bright Minds Biosciences Inc.? 19 Vestry Street New York, NY 10013 Attention:Mr. Ian McDonald, President and Chief Executive Officer Dear Sir: The undersigned, Eight Capital, as the sole agent and bookrunner (the ?Agent?), understands that Bright Minds Biosciences Inc.? (the ?Corporation?) proposes to issue up to 2,858,000 units of the Corporation (?Units?) at a pr |
|
| August 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 29, 2022 |
PROSPECTUS SUPPLEMENT To the Short Form Base Shelf Prospectus dated June 7, 2021 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. |
|
| August 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 24, 2022 |
BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS BRIGHT MINDS ANNOUNCES PRICING OF OVERNIGHT MARKETED OFFERING OF UNITS NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. |
|
| August 23, 2022 |
BRIGHT MINDS ANNOUNCES OVERNIGHT MARKETED OFFERING OF UNITS THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| August 18, 2022 |
Bright Minds Biosciences Comments on Recent Trading Activity Bright Minds Biosciences Comments on Recent Trading Activity Vancouver, BC ? August 18, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, is issuing this news release in response to a request by the Investment Industry Regulatory Organization of Canada (?IIROC?) to comment on recent trading activity of its stock. |
|
| August 15, 2022 |
Form 52-109F2R Certification of Refiled Interim Filings Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Bright Minds Biosciences Inc. |
|
| August 15, 2022 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) June 30, September 30, As at Notes 2022 2021 $ $ ASSETS Current Assets Cash and cash equi |
|
| August 15, 2022 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2022 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the third quarter fiscal year |
|
| August 15, 2022 |
Form 52-109F2R Certification of Refiled Interim Filings Form 52-109F2R Certification of Refiled Interim Filings This certificate is being filed on the same date that Bright Minds Biosciences Inc. |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offi |
|
| May 16, 2022 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| May 16, 2022 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and six months ended March 31, 2022 and 2021 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) March 31, September 30, As at Notes 2022 2021 $ $ ASSETS Current Assets Cash and cash equ |
|
| May 16, 2022 |
BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2022 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the second quarter fiscal y |
|
| May 16, 2022 |
Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the "interim filings") of Bright Minds Biosciences Inc. (the "issuer") for the interim period ended March 31, 2022. |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 12, 2022 |
For Immediate Release Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome - Review of Phase I ready BMB-101 and upcoming milestones - - Webcast to be held on May 19, 2022, 4:00pm ET - Vancouver, BC ? May 12, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that the Company will host a symposium with Key Opinion Leaders on Dravet Syndrome and recent therapeutic developments within the competitive landscape. |
|
| May 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive office) |
|
| May 2, 2022 |
Bright Minds Biosciences Establishes Scientific Advisory Board, Comprising Five Preeminent Physicians and Scientists Across Mental Health Specialties - Herbert Y. |
|
| April 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| April 19, 2022 |
For Immediate Release Bright Minds Biosciences to Host Symposium on Therapeutic Developments within Dravet Syndrome and Featuring a Panel with Key Opinion Leaders - Review of Phase I ready BMB-101 and upcoming milestones - - Conference call to be held on May 19, 2022, 10:00am ET - Vancouver, BC ? April 19, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Ian McDonald, Chief Executive Officer, Dr. |
|
| March 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| March 14, 2022 |
For Immediate Release Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial Vancouver, BC ? March 14, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced the successful completion of 28-day repeat-dose toxicity studies for its lead product, BMB-101. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| March 8, 2022 |
Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference For Immediate Release Bright Minds Biosciences to Present at the Oppenheimer 32nd Annual Healthcare Conference Vancouver, BC ? March 8, 2022 ? Bright Minds Biosciences (?Bright Minds,? ?BMB? or the ?Company?) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Company management will present virtually at the Oppenheimer 32nd Annual Healthcare Conference as follows: Date: Thursday, March 17, 2022 Time: 2:00PM ET Webcast: Click here An archived replay of the presentation will be available on the Company?s website immediately following the conference and will be available for 90 days at: https://brightmindsbio. |
|
| March 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive offic |
|
| March 2, 2022 |
EX-99.3 5 ex993.htm INFORMATION CIRCULAR RELATING TO THE ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 24, 2022 BRIGHT MINDS BIOSCIENCES INC. 19 Vestry Street New York, NY 10013 MANAGEMENT INFORMATION CIRCULAR (as at February 15, 2022, except as otherwise noted) This Management Information Circular (“Circular”) is furnished in connection with the solicitation of proxies by the managem |
|
| March 2, 2022 |
Proxy Card relating to Annual General Meeting of Shareholders to be held on March 24, 2022 EX-99.4 6 ex994.htm PROXY CARD RELATING TO ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 24, 2022 |
|
| March 2, 2022 |
BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS BRIGHT MINDS BIOSCIENCES INC. NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual general meeting (the ?Meeting?) of shareholders (the ?Shareholders?) of Bright Minds Biosciences Inc. (the ?Company?) will be held at the offices of McMillan LLP, Suite 1500, 1055 West Georgia Street, Vancouver, British Columbia, by way of in-person/teleconference call, on Thursday |
|
| March 2, 2022 |
January 12, 2022510 Burrard St, 3rd Floor Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: BRIGHT MINDS BIOSCIENCES INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General Meeting Record Date for Notice of Meeting : February 1 |
|
| March 2, 2022 |
BRIGHT MINDS BIOSCIENCES INC ? Interim Financial Statements Mark this box if you would like to receive Interim Financial Statements by mail. |
|
| February 15, 2022 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| February 15, 2022 |
Studies Completed & Other Milestones Accomplished: BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER ENDED DECEMBER 31, 2021 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis ("MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financial results for the first quarter fiscal |
|
| February 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| February 15, 2022 |
Form 52-109F2 Certification of Interim Filings Full Certificate Form 52-109F2 Certification of Interim Filings Full Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| February 15, 2022 |
Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three months ended December 31, 2021 and 2020 (Expressed in Canadian Dollars) Bright Minds Biosciences Inc. Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian dollars - Unaudited) December 31, September 30, As at Notes 2021 2021 $ $ ASSETS Current Assets Cash and cash equiv |
|
| January 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 1) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SE |
|
| January 5, 2022 |
Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference EX-99.1 2 ex991-20220104drug.htm NEWS RELEASE Bright Minds Biosciences to Present at the H.C. Wainwright Bioconnect Conference Vancouver, BC – January 4, 2022 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today ann |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2022 Commission File No. 001-40997 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive off |
|
| December 29, 2021 |
Section 302(a) Certification of CFO* EXHIBIT 12.2 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ryan Cheung, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in |
|
| December 29, 2021 |
Section 906 Certifications of CEO and CFO* EXHIBIT 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report of Bright Minds Biosciences Inc. on Form 20-F for the fiscal year ended September 30, 2021 filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned hereby certify that to the best of our |
|
| December 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC |
|
| December 29, 2021 |
Description of Registrant's Securities* EXHIBIT 2.2 DESCRIPTION OF REGISTRANT'S SECURITIES The following securities of our Company are registered under section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"): ? our Company's common shares are listed on the Nasdaq Capital Market ("Nasdaq"), under the symbol "DRUG". Jurisdiction of Incorporation Our Company was incorporated under the Business Corporations Act |
|
| December 29, 2021 |
Section 302(a) Certification of CEO* EXHIBIT 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Ian McDonald, certify that: 1. I have reviewed this Annual Report on Form 20-F of Bright Minds Biosciences Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, i |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 30, 2021 |
EX-99.1 2 ex991-20211130drug.htm NEWS RELEASE Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic Program for the Treatment of Mental Diseases — Hundreds of de novo patentable psychedelic-based compounds created through discovery program — — Company plans to announce lead molecule in first quarter of 2022 — Vancouver, BC – November 30, 2021 – Bright Minds Bioscience |
|
| November 3, 2021 |
Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG” EX-99.1 2 ex991-20211103drug.htm NEWS RELEASE DATED NOVEMBER 3, 2021 For Immediate Release Bright Minds Biosciences Commences Trading on the Nasdaq Under the Ticker Symbol “DRUG” Vancouver, BC – November 3, 2021 – Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsy |
|
| November 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive of |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 BRIGHT MINDS BIOSCIENCES INC. (Exact name of registrant as specified in its charter) British Columbia, Canada (State of incorporation or organization) Not applicable (I.R.S. Employer Identification |
|
| October 19, 2021 |
Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Bright Minds Biosciences to Present at the LD Micro Main Event Small Cap Investment Conference Vancouver, BC - October 6, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today a |
|
| October 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 19 Vestry Street, New York, NY 10013 (Address of principal executive off |
|
| September 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 1500 - 1055 West Georgia St. Vancouver, British Columbia, Canada, V6E |
|
| September 27, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 For Immediate Release Bright Minds Biosciences Provides Scientific Update - Lead program, BMB-101, advances to IND-enabling toxicology studies with the aim of commencing human trials in 1H 2022 - Vancouver, BC -September 22, 2021 - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on |
|
| September 17, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Bright Minds Biosciences to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference; Shares Now Eligible for DTC Clearance VANCOUVER, British Columbia, Sept. 08, 2021 (GLOBE NEWSWIRE) - Bright Minds Biosciences ("Bright Minds," "BMB" or the "Company") (CSE: DRUG) (OTCQB: BMBIF), a biotechnology company focused on developing novel drugs |
|
| September 17, 2021 |
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Ian McDonald, Chief Executive Officer of Bright Minds Biosciences Inc. |
|
| September 17, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the three and nine months ended June 30, 2021 and 2020 (Unaudited) (Expressed in Canadian Dollars) June 30, September 30, As at Notes 2021 2020 $ $ ASSETS Current Assets Cash and cash equivalents 9 22,006,997 799,929 Sales tax receivable 77,984 - Prepaids 7 128,074 78,287 22 |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 1500 - 1055 West Georgia St. Vancouver, British Columbia, Canada, V6E |
|
| September 17, 2021 |
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Ryan Cheung, Chief Financial Officer of Bright Minds Biosciences Inc. |
|
| September 17, 2021 |
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 4) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A |
|
| September 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 1500 - 1055 West Georgia St. Vancouver, British Columbia, Canada, V6E 4N7 |
|
| September 17, 2021 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALSIS FOR THE THIRD QUARTER ENDED JUNE 30, 2021 (All amounts expressed in Canadian dollars, unless otherwise stated) This Management Discussion and Analysis (this "MD&A") provides a detailed analysis of the business of Bright Minds Biosciences Inc. (the "Company") and describes the Company's financia |
|
| September 16, 2021 |
Reply to the Attention of Michael Shannon Direct Line (604) 893-7638 Direct Fax (604) 685-7084 Email Address michael. |
|
| August 27, 2021 |
ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 3) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A |
|
| August 27, 2021 |
Reply to the Attention of Michael Shannon Direct Line (604) 893-7638 Direct Fax (604) 685-7084 Email Address michael. |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2021 Commission File No. 000-56296 BRIGHT MINDS BIOSCIENCES INC. (Translation of registrant's name into English) 1500 - 1055 West Georgia St. Vancouver, British Columbia, Canada, V6E 4N7 |
|
| August 18, 2021 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 For Immediate Release Bright Minds Biosciences ("BMB") Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity - BMB proprietary 5-HT2C agonist, BMB-101, shows efficacy in pre-clinical models of Dravet Syndrome/Epilepsy, with lower seizure duration and frequency - - Effect of BMB compounds was consistent with other anti-epileptics such as f |
|
| August 13, 2021 |
Reply to the Attention of Michael Shannon Direct Line (604) 893-7638 Direct Fax (604) 685-7084 Email Address michael. |
|
| August 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F/A (Amendment No. 2) ? REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) or 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE A |
